Accès ouvert
2025
article
OpenAlex
Obbina Abani, Amr E. Abbas, Fatima H. Abbas, Kaja Abbas et autres
BACKGROUND: Sotrovimab is a neutralising monoclonal antibody targeting the SARS-CoV-2 spike protein. We aimed to evaluate the efficacy and safety of sotrovimab in the RECOVERY trial, an investigator-initiated, individually randomised, controlled, open-label, adaptive platform trial testing treatments for patients admitted to hospital …
Accès ouvert
2025
article
OpenAlex
Obbina Abani, Amr E. Abbas, Fatima H. Abbas, Jonathan Raihan Abbas et autres
BACKGROUND: Molnupiravir and nirmatrelvir-ritonavir are oral antivirals that have shown efficacy in preventing disease progression in outpatients with COVID-19. We aimed to evaluate these treatments for patients hospitalised with COVID-19 pneumonia, for whom data on these antivirals are scarce. METHODS: The RECOVERY …
Accès ouvert
2025
article
OpenAlex
Obbina Abani, Amr E. Abbas, Fatima H. Abbas, Jaffar Abbas et autres
Background: Low dose corticosteroids (e.g., 6 mg dexamethasone) have been shown to reduce mortality for hypoxic COVID-19 patients. We have previously reported that higher dose corticosteroids cause harm in patients with clinical hypoxia but not receiving ventilatory support (the combination of non-invasive …
Accès ouvert
2023
article
OpenAlex
Obbina Abani, Amr E. Abbas, Fatima H. Abbas, Jonathan Raihan Abbas et autres
BACKGROUND: Empagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic, and haemodynamic effects. The RECOVERY trial aimed to assess its safety and efficacy in patients admitted to hospital with COVID-19. METHODS: In the randomised, controlled, …